A 32-year-old woman with type 2 diabetes mellitus suffering from morbid obesity with BMI 45,14?kg/m2 was operated on. Not only the type 2DM but also one of its complication known as necrobiosis lipoidica diabeticorum remitted postoperatively. Obesity should no longer be regarded simply as a cosmetic problem affecting certain individuals but an epidemic that threatens global well-being. It causes or exacerbates many health problems, and in particular, it is associated with the type 2 diabetes. Necrobiosis lipoidica is a granulomatous skin disease of unknown etiology, associated mainly with diabetes mellitus. We presented in this paper a morbid obese case of necrobiosis lipoidica diabeticorum with dramatic good response to bariatric surgery. 1. Introduction Obesity should no longer be regarded simply as a cosmetic problem affecting certain individuals but an epidemic that threatens global well-being. It causes or exacerbates many health problems, and in particular, it is associated with the T2DM. Necrobiosis lipoidica is a granulomatous skin disease of unknown etiology, associated with diabetes mellitus which responds with limited success to many treatment options. We report in this paper a case of NLD treated successfully with bariatric/metabolic surgery. 2. Case Report A 32-year-old woman was operated on for morbid obesity with BMI 45,14?kg/m2 in April 2011. She had diabetes mellitus for 12 years. She has been under 1?U/kg/day insulin therapy since 2002 (2/3 (96?U) insulin aspart and 1/3 (30?U) insulin glargine). She had bilateral, almost circumferential, persistent plaques with depressed central areas and elevated peripheral rings over legs. The lesions are ulcerated and oozing with moderate to severe pain which partially respond to pain killers (Figure 1). The punch biopsies were performed, and the histopathologic examination of the lesions revealed the loss of epidermis rete associated with degenerative collagenous plaques in the dermis with peripheral histiocytic palisades (Figure 2(a)). Also associated subcutaneous multiple granuloma with plasma cells, lymphocytes and multinuclear giant cells (Figure 2(b)). The pathologic diagnosis was necrobiosis lipoidica. She was prescribed steroid for topical use and was treated with psoralen plus ultraviolet A photochemotherapy and also with different kind of skin dressings which were unsuccessful. She had undergone laparoscopic minigastric bypass. From the first postoperative day, she left the insulin and pain killers and after a month the lesions on the left leg subsided. She experienced the same regression
References
[1]
F. Branca, H. Nikogosian, and T. Lobstein, Eds., The Challenge of Obesity in the WHO European Region and the Strategies for Response, WHO, Copenhagen, Denmark, 2007.
[2]
J. C. Seidell, “Time trends in obesity: an epidemiological perspective,” Hormone and Metabolic Research, vol. 29, no. 4, pp. 155–158, 1997.
[3]
S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004.
[4]
G. Mingrone and L. Castagneto-Gissey, “Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery,” Diabetes and Metabolism, vol. 35, no. 6, part 2, pp. 518–523, 2009.
[5]
F. Rubino, A. Forgione, D. E. Cummings et al., “The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes,” Annals of Surgery, vol. 244, no. 5, pp. 741–749, 2006.
[6]
F. Rubino and J. Marescaux, “Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease,” Annals of Surgery, vol. 239, no. 1, pp. 1–11, 2004.
[7]
H. Buchwald, R. Estok, K. Fahrbach et al., “Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis,” American Journal of Medicine, vol. 122, no. 3, pp. 248–256, 2009.
[8]
J. B. Dixon, C. W. le Roux, F. Rubino, and P. Zimmet, “Bariatric surgery for type 2 diabetes,” The Lancet, vol. 379, no. 9833, pp. 2300–2311, 2012.
[9]
P. R. Schauer, S. R. Kashyap, K. Wolski, et al., “Bariatric surgery versus intensive medical therapy in obese patients with diabetes,” The New England Journal of Medicine, vol. 366, no. 17, pp. 1567–1576, 2012.
[10]
K. Weismann and D. A. Burns, “Skin disorders in diabetes mellitus,” in Rook’s Textbook of Dermatology, T. Burns, S. Breathnach, N. Cox, and C. Griffiths, Eds., pp. 57.106–57.123, Blackwell Science Oxford, Oxford, UK, 7th edition, 2004.
[11]
V. N. Sehgal, S. N. Bhattacharya, and P. Verma, “Juvenile, insulin-dependent diabetes mellitus, type 1-related dermatoses,” Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 6, pp. 625–636, 2011.
[12]
M. Kavala, S. Sudogan, I. Zindanci et al., “Significant improvement in ulcerative necrobiosis lipoidica with hydroxychloroquine,” International Journal of Dermatology, vol. 49, no. 4, pp. 467–469, 2010.
[13]
S. Radakovic, M. Weber, and A. Tanew, “Dramatic response of chronic ulcerating necrobiosis lipoidica to ultraviolet A1 phototherapy,” Photodermatology Photoimmunology and Photomedicine, vol. 26, no. 6, pp. 327–329, 2010.
[14]
A. Patsatsi, A. Kyriakou, and D. Sotiriadis, “Necrobiosis lipoidica: early diagnosis and treatment with tacrolimus,” Case Reports in Dermatology, vol. 3, no. 1, pp. 89–93, 2011.